The Expanding Market for Weight-Loss Drugs
This week, Hims & Hers announced the launch of their own off brand weight-loss injection, sparking a boost in their stock prices. Melissa Lee, Host of CNBC's Fast Money, takes us into the marketplace for GLP-1 agonist drugs, Ozempic dupes sold online, and what the popularity of these drugs on Wall Street means for patients.
Audio is streamed directly from the publisher (pscrb.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
It's impossible to ignore the chatter about Ozempic, Wegovy, and other weight-loss medications that have hit the market in the last few years. This week, Hims & Hers -- a telehealth company known for discreetly treating erectile dysfunction, balding, and other sensitive conditions -- announced the launch of their own off brand weight-loss injection, sparking a boost in their stock prices. Melissa Lee, Host of CNBC's Fast Money, takes us into the marketplace for GLP-1 agonist drugs, Ozempic dupes sold online, and what the popularity of these drugs on Wall Street means for patients.